Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Firms Join For Drug Conjugates
by Ann M. Thayer
June 24, 2013
| A version of this story appeared in
Volume 91, Issue 25
Denmark’s Genmab and Switzerland’s ADC Therapeutics will begin preclinical development of an antibody-drug conjugate that combines Genmab’s HuMax-TAC antibody and ADC’s highly potent pyrrolobenzodiazepine-based drug and linker technology. HuMax-TAC targets the CD25 antigen expressed on hematological tumors. Separately, San Diego-based Ambrx and China’s Zhejiang Medicine Co. will develop Ambrx’ ARX788, which targets Her2-positive breast cancer. Chinese service provider WuXi AppTec will help make the drug, antibody, and conjugate, and support preclinical and clinical trial work.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter